Ironwood Pharma Elects Directors at Annual Meeting

Ironwood Pharma ( (IRWD) ) has shared an update.

On June 10, 2025, Ironwood Pharmaceuticals held its Annual Meeting of Stockholders, where nine directors were elected to serve a one-year term on the board. Additionally, stockholders approved executive compensation and ratified Ernst & Young LLP as the independent public accounting firm for 2025.

The most recent analyst rating on (IRWD) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.

Spark’s Take on IRWD Stock

According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.

Ironwood Pharma’s overall stock score is hindered by financial challenges, notably a negative equity position and declining revenues. The technical analysis reflects a bearish trend, compounded by valuation concerns due to a negative P/E ratio. Moreover, the potential delisting risk following the Nasdaq deficiency letter further dampens investor sentiment. Positive cash flow remains a key strength, although overshadowed by broader financial and operational risks.

To see Spark’s full report on IRWD stock, click here.

More about Ironwood Pharma

Ironwood Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines.

Average Trading Volume: 3,448,254

Technical Sentiment Signal: Sell

Current Market Cap: $129.3M

For a thorough assessment of IRWD stock, go to TipRanks’ Stock Analysis page.